Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours

BACKGROUND: Hypoxia can activate autophagy, a self-digest adaptive process that maintains cell turnover. Mammalian target of rapamycin (mTOR) inhibitors are used to treat cancer but also stimulate autophagy. METHODS: Human mammary cancer cells and derived xenografts were used to examine whether hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Seront, E, Boidot, R, Bouzin, C, Karroum, O, Jordan, B F, Gallez, B, Machiels, J-P, Feron, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833227/
https://www.ncbi.nlm.nih.gov/pubmed/24157830
http://dx.doi.org/10.1038/bjc.2013.644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833227/
https://www.ncbi.nlm.nih.gov/pubmed/24157830
http://dx.doi.org/10.1038/bjc.2013.644

Ejemplares similares